Autoimmunity as a Predisposition for Infectious Diseases


article has not abstract


Published in the journal: . PLoS Pathog 6(11): e32767. doi:10.1371/journal.ppat.1001077
Category: Opinion
doi: 10.1371/journal.ppat.1001077

Summary

article has not abstract

Autoimmunity refers to an inappropriate immune response against self-components of the host that results in pathological conditions. Autoimmune diseases are characterized by an activation of autoreactive T and B cells, are associated in some cases with the production of pathogenic autoantibodies against self-molecules, culminating in inflammation and tissue damage. The reasons for the breakdown of tolerance mechanisms leading to autoimmunity are not clearly known. However, a combination of genetic, immunological, and environmental factors plays a critical role in the pathogenesis of autoimmunity [1][5].

Autoimmunity Can Predispose to Infectious Diseases

During the course of autoimmunity, autoantibodies that can neutralize key components of the immune system that are essential in mounting anti-microbial responses may be produced (Figure 1). These autoantibodies might either exacerbate ongoing infectious diseases or predispose the individual to an increased risk of bacterial, viral, and opportunistic fungal infections. For example, cytokines play a critical role in the process of mounting anti-microbial responses due to their ability to regulate the innate and adaptive immune systems, in polarizing T cell responses, and by acting as effector molecules. Thus, IL-12 mediates Th1 cell differentiation and IL-4 influences Th2 differentiation. IL-6, IL-21, TGF-β, IL-1β, and IL-23 are critical for the differentiation and expansion of Th17 cells. Th1 cells produce cytokines IFN-γ and IL-2, and confer protection against intracellular pathogens (viruses and intracellular bacteria such as Mycobacterium and Salmonella). Th2 cells produce IL-4, IL-5, and IL-13, and are important to clear extracellular pathogens and parasites. Th-17 cells secrete IL-17, IL-21, and IL-22, and provide protection against several extracellular pathogens, including fungi such as Candida (Figure 1) [6][9]. In addition, type I IFNs have a critical role in anti-viral immunity and in modulating T and B cell responses. Therefore, it can be conceived that the development of neutralizing antibodies against any of these cytokines as a consequence of autoimmunity affects the cellular functions and clearance of pathogens and predisposes the host to infectious diseases. This is further supported by reports of a high prevalence of infections in autoimmune patients treated with neutralizing monoclonal antibodies to inflammatory cytokines. Patients with rheumatoid arthritis, Crohn's disease, or psoriasis treated on a chronic basis with monoclonal antibodies to TNF-α are predisposed to mycobacterial, listerial, and viral infections [10][12].

Host immune response to pathogens and predisposition to infections due to autoimmunity.
Fig. 1. Host immune response to pathogens and predisposition to infections due to autoimmunity.
Antigens from invading pathogens are recognized and presented by innate immune cells (A) such as macrophages and dendritic cells to CD4+ and CD8+ T cells (CTL) (B). CD8+ T cells recognize endogenous antigens presented by MHC class I molecules and exert cytotoxic functions upon activation. CD4+ T cells recognize antigens presented in the context of MHC class II molecules, and under the influence of innate cells and cytokine milieu, CD4+ T cells can be polarized into different subsets such as Th1, Th2, Th17, and regulatory T cells (Tregs) that secrete distinct cytokines. CD4+ T cells provide help to B cells to produce antigen-specific antibodies (C). However, due to autoimmunity, neutralizing autoantibodies can be produced against any of these key components of the immune system critical for mounting anti-microbial responses and might either predispose to an increased risk of bacterial, viral, and opportunistic fungal infections or exacerbate the ongoing infectious diseases. Indeed, in patients with infections, the occurrence of neutralizing autoantibodies against several key cytokines such as IFN-γ, IL-6, GM-CSF, IL-17, and IL-22 (highlighted in red boxes) that interfere with the host immune response to pathogens have been demonstrated. In addition, autoantibodies are also reported against type I IFNs and IL-12 that might play role in predisposition to infections (highlighted in blue boxes). CTLA-4, cytotoxic T lymphocyte antigen-4; CTL, cytotoxic T lymphocyte; FasL, Fas ligand; GM-CSF, granulocyte/macrophage–colony stimulating factor.

Specific Examples of Autoimmunity Favoring Infectious Diseases

Several reports have now demonstrated the occurrence of neutralizing autoantibodies against cytokines in patients with infections. These reports thus provide a pointer towards a previously unknown link between autoimmune responses and predisposition to infectious diseases.

A correlation between neutralizing autoantibodies to IFN-γ and mycobacterial infections has been reported [13][20]. Moreover, the clinical features of patients with anti-IFN-γ immunoglobulin G (IgG) are analogous to those with genetic defects in the IFN-γ/IL-12 pathway, which is characterized by progressive or disseminated infection with mycobacteria of low virulence, indicating that anti-IFN-γ IgG induces an acquired immunodeficiency state and predisposes to mycobacterial infections [13][20]. These anti-IFN-γ IgG neutralized IFN-γ in whole blood culture, inhibited IFN-γ-dependent phosphorylation of STAT-1 and production of TNF-α and IL-12 by normal peripheral blood mononuclear cells (PBMCs) and macrophages, and inhibited HLA-DR expression in normal monocytes [14][17]. In another study, one patient's serum was shown to inhibit IFN-γ-mediated upregulation of MHC class I on Jurkat cells [20]. Given the critical role of the type I cytokine pathway in the immune response to mycobacterial infections [21], these reports provide direct evidence for how anti-IFN-γ autoantibodies can affect protective anti-mycobacterial immunity.

Recurrent staphylococcal cellulitis and subcutaneous abscesses were reported in a child with autoantibodies against IL-6 [22]. These anti-IL-6 autoantibodies inhibited IL-6-mediated STAT3 phosphorylation and C-reactive protein (CRP) production in Hep3B cells. Since IL-6 is pivotal for CRP induction, these results indicated that anti-IL-6 autoantibodies contributed to the lack of CRP response in this patient during staphylococcal infections. In addition, IL-6- deficient mice have been shown to be susceptible to various pyogenic infections, including Streptococcus pneumoniae, Pseudomonas aeruginosa, and Klebsiella pneumoniae [23][26]. Interestingly, autoantibodies to IL-6 were not identified in other patients with severe staphylococcal diseases and hence suggest that anti-IL-6 autoantibodies were not generated due to molecular mimicry with Staphylococcus aureus. In addition, the course of clinical events in the patient was suggestive of an occurrence of anti-IL-6 autoantibodies that preceded staphylococcal infection.

Patients suffering from pulmonary alveolar proteinosis (PAP) present with neutralizing antibodies against granulocyte/macrophage colony–stimulating factor (GM-CSF) and show high mortality due to infection [27]. GM-CSF has a key role in enhancing the antimicrobial activities of neutrophils and macrophages by augmenting the expression of CD11b, an adhesion molecule that mediates neutrophil adhesion to endothelial cells, and hence promoting the recruitment of neutrophils to the site of infection; promoting the differentiation of macrophages and dendritic cells (DCs); and by priming the phagocytosis and bactericidal activities of these cells. Low levels of GM-CSF autoantibodies are present in healthy individuals. These autoantibodies are implicated in scavenging and neutralizing free GM-CSF and to regulate myeloid cell functions and GM-CSF-mediated inflammation and autoimmunity [28]. However, active PAP patients have high amounts of GM-CSF autoantibodies that impair the antimicrobial functions of neutrophils, macrophages, and the expression of CD11b [29]. In addition, these autoantibodies exist abundantly in the lungs, and by effectively blocking GM-CSF binding to its receptor, they specifically inhibit alveolar macrophage differentiation, phagocytosis, and surfactant catabolism [30], [31]. Patient-derived GM-CSF autoantibodies reproduced PAP in experimental non-human primate and murine models [29], [32], while individuals with mutations in GM-CSF receptor are also affected with PAP [33]. These results thus confirm the causal relationship between defective GM-CSF function, autoantibodies, and PAP.

Th17 cytokines are implicated in protection against fungal infections, including Candida at mucosal surfaces, and hence neutralizing antibodies to Th17 cytokines can predispose to fungal infections [8], [34], [35]. Interestingly, neutralizing autoantibodies against Th17 cell cytokines IL-17A, IL-17F, and IL-22 have been reported in chronic mucocutaneous candidiasis (CMC) patients with autoimmune polyendocrinopathy syndrome-1 (APS-1) or thymoma [36], [37]. Of particular importance, the autoantibody titers were high before the onset of CMC. Further, individuals with mutations in STAT3 and IL-12RB1 showed impaired development of Th17 cells and higher susceptibility to candidiasis [38].

In addition to the above examples, autoantibodies to type I IFNs (such as IFN-α2, IFN-ω), IL-12, and TNF-α were also identified in patients with autoimmune and rheumatic diseases and in those with chronic infections [39]. Intractable (even fatal) infections in myasthenia gravis patients with thymoma might be related to high titers of anti-IL-12 and anti-IFNα autoantibodies that can reduce an IFN-γ response with a bias towards an IL-4 response [40].

Taken together, anti-cytokine autoantibodies induce an acquired immune-compromised state that predisposes the host to infections. Although autoantibodies to several cytokines are relatively widespread, they rarely neutralize to a significant extent [39]. Further, anti-cytokine autoantibodies do not seem to have co-distribution, and cytokines do have redundant functions; hence, severe infections are not common unless as described above, and neutralizing autoantibodies are developed against specific cytokines that are key in an anti-microbial response.

In view of these findings, we suggest that patients with uncontrolled or repeated infections despite antimicrobial therapy should be considered for screening and evaluating autoimmunity. Although reported examples are of autoantibodies to cytokines, the occurrence of autoantibodies that target either molecules implicated in the recognition of pathogens (such as Toll-like receptors and lectin receptors) or antigen presenting and co-stimulatory molecules cannot be ruled out. Indeed, genetic defects or polymorphisms in pattern recognition receptors and their signaling pathways and susceptibility to infections have been reported [41][44].

Enigma of Induction of Anti-Cytokine Autoantibodies

Despite the reports of anti-cytokine antibodies in several malignant or infectious diseases and their low titers in healthy individuals, the high titers are predominant in autoimmune diseases [39]. Consensually, anti-cytokine antibodies against type I IFNs, IL-12, IL-17, and IL-22 are found in APS-1 or myasthenia gravis patients associated with or without thymoma [36], [37], [45]. Here, AIRE (autoimmune regulator), a novel gene that regulates peripheral self-antigen expression in medullary thymic epithelia and DCs, is mutated, leading to disturbed self-tolerance mechanisms. Thus, APS-1 patients may display autoantibodies against type I IFNs and IL-17 cytokines as a result of impaired AIRE-dependent tolerance induction. Further, extensive work by the Meager and Willcox group provided clues toward autoimmunizing mechanisms and innate cells (plasmacytoid and myeloid DCs) in the induction of anti-cytokine antibodies to type I IFNs and IL-12 [39], [40], [45].

Therefore, it is probable that autoantibodies are produced as a consequence of infections and these autoantibodies subsequently exacerbate the infectious diseases or, alternatively, a cryptic autoimmunity develops due to unknown reasons that predispose the individual to infections. Infectious agents and vaccines are often thought to be one of the environmental factors that induce autoimmunity either by molecular mimicry, epitope spreading, bystander activation of immune system, or polyclonal activation of immune cells [2], [3]. It is thus likely that in case of chronic persistent diseases such as tuberculosis, a pathogen might trigger the autoimmune process by one of these mechanisms. Indeed, the majority of patients with autoantibodies and mycobacterial infections originated from disease-endemic areas [13][20]. Therefore, dissection of underlying causes of autoimmunity such as genetic polymorphisms, gene deficiency, or environmental factors might shed light on these unanswered questions.

Therapeutic Options for Autoimmunity-Associated Infectious Diseases

Therapeutic strategies for autoimmunity-associated infectious diseases should be aimed at controlling the infection as well as inhibiting the autoimmune response: blocking autoantibody-producing B cells and neutralizing autoantibodies. In this context, a combination of anti-microbial agents and immunosuppressive treatments represents a classical line of therapy for autoimmunity-associated infectious diseases. Plasmapheresis that removes autoantibodies or supplementing exogenous cytokines (against which autoantibodies have developed) are other potential therapeutic strategies. However, such therapeutic strategies do not eliminate the source of autoantibodies, i.e., autoantibody-producing B cells and plasma cells.

Autoantibody-producing B cells can be eliminated by B cell–targeted therapies (such as monoclonal antibodies to CD20, CD19, and CD22 or to B cell-activating factor (BAFF) [46][48]). However, repeated cycles of B cell–targeted therapies can lead to a reduction in total immunoglobulin level and predisposition to serious infections [49], [50]. Also, these therapeutic agents do not target antibody-producing plasma cells.

In view of proven safety and efficacy in diverse autoimmune diseases, polyclonal intravenous immunoglobulin (IVIg) in combination with anti-microbial agents represents an attractive therapy for autoimmunity-associated infections [51]. IVIg targets both cellular and soluble mediators of autoimmunity and inhibits the disease by multi-pronged mutually nonexclusive mechanisms such as neutralization of anti-cytokine autoantibodies by broad-spectrum anti-idiotypic antibodies, induction of B cell tolerance, inhibition of cellular proliferation, regulation of immunoglobulin repertoire, suppression of innate antigen presenting cells and inhibition of T cell help to B cells, and expansion of CD4+CD25+ regulatory T cells, the cells that are critical for maintaining immune tolerance and to suppress autoimmunity [51], [52]. Since IVIg is obtained from pooled plasma of several thousand healthy blood donors, based on the exposure of donors to infectious diseases and vaccinations, IVIg contains antibodies to a wide range of infectious agents, and hence these anti-microbial antibodies within IVIg preparations can directly neutralize pathogens [53]. However, determining an effective dose regimen and duration of IVIg therapy needs further investigation.

In our opinion, considering all therapeutic options, a “triple” combination of anti-microbial agents, B cell–targeted therapies, and IVIg represents the most appropriate and ideal method for treating autoimmunity-associated infectious diseases. Indeed, the combination of B cell–targeted therapies and IVIg has been successfully used in several autoimmune and inflammatory diseases [54], [55].

Accession Numbers/ID Numbers for Genes and Proteins: UniProtKB

The UniProt (http://www.uniprot.org/) accession numbers for genes and proteins discussed in this paper are IL-17A, Q16552; IL-17F, Q96PD4; IL-21, Q9HBE4; IL-22, Q9GZX6; IL-23, Q9NPF7; IL-12RB2, Q99665; IFN-γ, P01579; GM-CSF, P01587; IL-6, P05231; IL-4, P05112; IL-5, P05113; IL-13, P35225; BAFF (BLyS), Q9Y275; IFN-α2, P01563; IFN-ω, P05000; TNF-α, P01375; IL-1β, P01584; IL-12 p40 (IL-12B), P29460; IL-12 p35 (IL-12A), P29459; AIRE, O43918; STAT3, P40763; HLA-DR, O19685; CD20, P11836; CD11b, P11215; CD19, P15391; CD22, P20273.


Zdroje

1. ShoenfeldY

1994 Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 8 1296 1301

2. KivityS

Agmon-LevinN

BlankM

ShoenfeldY

2009 Infections and autoimmunity—friends or foes? Trends Immunol 30 409 414

3. Agmon-LevinN

PazZ

IsraeliE

ShoenfeldY

2009 Vaccines and autoimmunity. Nat Rev Rheumatol 5 648 652

4. InvernizziP

GershwinME

2009 The genetics of human autoimmune disease. J Autoimmun 33 290 299

5. HewagamaA

RichardsonB

2009 The genetics and epigenetics of autoimmune diseases. J Autoimmun 33 3 11

6. ZhuJ

PaulWE

2008 CD4 T cells: fates, functions, and faults. Blood 112 1557 1569

7. BettelliE

KornT

OukkaM

KuchrooVK

2008 Induction and effector functions of T(H)17 cells. Nature 453 1051 1057

8. DubinPJ

KollsJK

2008 Th17 cytokines and mucosal immunity. Immunol Rev 226 160 171

9. AimaniandaV

HaenslerJ

Lacroix-DesmazesS

KaveriSV

BayryJ

2009 Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 30 287 295

10. DinarelloCA

2003 Anti-cytokine therapeutics and infections. Vaccine 21 Suppl 2 S24 34

11. WinthropKL

ChillerT

2009 Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 5 405 410

12. Marodi L, Casanova JL Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies? Nat Rev Immunol 10 299 300

13. MadariagaL

AmurrioC

MartinG

Garcia-CebrianF

BicandiJ

1998 Detection of anti-interferon-γ autoantibodies in subjects infected by Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2 62 68

14. DoffingerR

HelbertMR

Barcenas-MoralesG

YangK

DupuisS

2004 Autoantibodies to interferon-γ in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis 38 e10 14

15. HoflichC

SabatR

RosseauS

TemmesfeldB

SlevogtH

2004 Naturally occurring anti-IFN-γ autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103 673 675

16. KampmannB

HemingwayC

StephensA

DavidsonR

GoodsallA

2005 Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J Clin Invest 115 2480 2488

17. PatelSY

DingL

BrownMR

LantzL

GayT

2005 Anti-IFN-γ autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 175 4769 4776

18. TanakaY

HoriT

ItoK

FujitaT

IshikawaT

2007 Disseminated Mycobacterium avium complex infection in a patient with autoantibody to interferon-γ. Intern Med 46 1005 1009

19. KoyaT

TsubataC

KagamuH

KoyamaK

HayashiM

2009 Anti-interferon-γ autoantibody in a patient with disseminated Mycobacterium avium complex. J Infect Chemother 15 118 122

20. BaerleckenN

JacobsR

StollM

SchmidtRE

WitteT

2009 Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-γ autoantibody. Clin Infect Dis 49 e76 78

21. CasanovaJL

AbelL

2002 Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 20 581 620

22. PuelA

PicardC

LorrotM

PonsC

ChrabiehM

2008 Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 180 647 654

23. van der PollT

KeoghCV

GuiraoX

BuurmanWA

KopfM

1997 Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 176 439 444

24. van EnckevortFH

SweepCG

SpanPN

NeteaMG

HermusAR

2001 Reduced adrenal response and increased mortality after systemic Klebsiella pneumoniae infection in interleukin-6-deficient mice. Eur Cytokine Netw 12 581 586

25. ColeN

BaoS

StapletonF

ThakurA

HusbandAJ

2003 Pseudomonas aeruginosa keratitis in IL-6-deficient mice. Int Arch Allergy Immunol 130 165 172

26. DiaoH

KohanawaM

2005 Endogenous interleukin-6 plays a crucial protective role in streptococcal toxic shock syndrome via suppression of tumor necrosis factor alpha production. Infect Immun 73 3745 3748

27. KitamuraT

TanakaN

WatanabeJ

Uchida, KanegasakiS

1999 Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190 875 880

28. UchidaK

NakataK

SuzukiT

LuisettiM

WatanabeM

2009 Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 113 2547 2556

29. UchidaK

BeckDC

YamamotoT

BerclazPY

AbeS

2007 GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 356 567 579

30. UchidaK

NakataK

TrapnellBC

TerakawaT

HamanoE

2004 High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 103 1089 1098

31. NakataK

KanazawaH

WatanabeM

2006 Why does the autoantibody against granulocyte-macrophage colony-stimulating factor cause lesions only in the lung? Respirology 11 Suppl S65 69

32. SakagamiT

UchidaK

SuzukiT

CareyBC

WoodRE

2009 Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 361 2679 2681

33. SuzukiT

SakagamiT

RubinBK

NogeeLM

WoodRE

2008 Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 205 2703 2710

34. ContiHR

ShenF

NayyarN

StocumE

SunJN

2009 Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206 299 311

35. LinL

IbrahimAS

XuX

FarberJM

AvanesianV

2009 Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5 e1000703 doi:10.1371/journal.ppat.1000703

36. KisandK

Boe WolffAS

PodkrajsekKT

TserelL

LinkM

2010 Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207 299 308

37. PuelA

DoffingerR

NatividadA

ChrabiehM

Barcenas-MoralesG

2010 Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207 291 297

38. de BeaucoudreyL

PuelA

Filipe-SantosO

CobatA

GhandilP

2008 Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 205 1543 1550

39. MeagerA

WadhwaM

DilgerP

BirdC

ThorpeR

2003 Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-α, interferon-ω and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 132 128 136

40. ZhangW

LiuJL

MeagerA

Newsom-DavisJ

WillcoxN

2003 Autoantibodies to IL-12 in myasthenia gravis patients with thymoma; effects on the IFN-γ responses of healthy CD4+ T cells. J Neuroimmunol 139 102 108

41. van de VosseE

van DisselJT

OttenhoffTH

2009 Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect Dis 9 688 698

42. FerwerdaB

FerwerdaG

PlantingaTS

WillmentJA

van SprielAB

2009 Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 361 1760 1767

43. GlockerEO

HennigsA

NabaviM

SchafferAA

WoellnerC

2009 A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 361 1727 1735

44. CawsM

ThwaitesG

DunstanS

HawnTR

LanNT

2008 The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 4 e1000034 doi:10.1371/journal.ppat.1000034

45. MeagerA

VisvalingamK

PetersonP

MollK

MurumagiA

2006 Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 3 e289 doi:10.1371/journal.pmed.0030289

46. EdwardsJC

CambridgeG

2006 B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 394 403

47. TedderTF

2009 CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 5 572 577

48. DornerT

RadbruchA

BurmesterGR

2009 B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5 433 441

49. KorhonenR

MoilanenE

2009 Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 106 13 21

50. McDonaldV

LeandroM

2009 Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol 146 233 246

51. KazatchkineMD

KaveriSV

2001 Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 747 755

52. Tha-InT

BayryJ

MetselaarHJ

KaveriSV

KwekkeboomJ

2008 Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29 608 615

53. BayryJ

Lacroix-DesmazesS

KazatchkineMD

KaveriSV

2004 Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 25 306 310

54. AhmedAR

SpigelmanZ

CavaciniLA

PosnerMR

2006 Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355 1772 1779

55. VoAA

LukovskyM

ToyodaM

WangJ

ReinsmoenNL

2008 Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359 242 251

Štítky
Hygiena a epidemiologie Infekční lékařství Laboratoř

Článek vyšel v časopise

PLOS Pathogens


2010 Číslo 11

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Krvácení v důsledku portální hypertenze při jaterní cirhóze – od pohledu záchranné služby až po závěrečný hepato-gastroenterologický pohled
nový kurz
Autoři: PhDr. Petr Jaššo, MBA, MUDr. Hynek Fiala, Ph.D., prof. MUDr. Radan Brůha, CSc., MUDr. Tomáš Fejfar, Ph.D., MUDr. David Astapenko, Ph.D., prof. MUDr. Vladimír Černý, Ph.D.

Rozšíření možností lokální terapie atopické dermatitidy v ordinaci praktického lékaře či alergologa
Autoři: MUDr. Nina Benáková, Ph.D.

Léčba bolesti v ordinaci praktického lékaře
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se